Genetically modified murine skeletal myoblasts were tissue engineered
in vitro into organ-like structures (organoids) containing only postmi
totic myofibers secreting pharmacological levels of recombinant human
growth hormone (rhGH). Subcutaneous organoid implantation under tensio
n led to the rapid and stable appearance of physiological sera levels
of rhGH for up to 12 weeks, whereas surgical removal led to its rapid
disappearance. Reversible delivery of bioactive compounds from postmit
otic cells in tissue engineered organs has several advantages over oth
er forms of muscle gene therapy.